Purposeful
& Passionate

In a dynamic and rapidly changing industry, GSL has seized on the opportunity to apply superior scientific expertise,  our unique products and patented technologies to improve the global healthcare sector by deploying an innovative genomic-based AI and quantum platform for clinical trials, point of care solutions and personalized consumer health.

DNA Technology

SUPERIOR SCIENCE, INSPIRED PRODUCTS AND EXCEPTIONAL OUTCOMES

We are a team of experienced business professionals, entrepreneurs, doctors, professors, researchers and administrators with a common goal: to improve the global healthcare sector.

" We are an innovative healthcare company with a vision to improve the global healthcare sector by deploying an innovative genomic-based AI and quantum platform for clinical trials, point of care solutions and personalized consumer health.."

We are innovators in the development of genomic-based AI and quantum platform for clinical trials.

We are thought leaders, advancing research to unlock the full potential of point of care solutions and therapies.

We provide quality and efficacy to the development of a comprehensive suite of novel, science-driven, biopharmaceuticals.

Partner Institutions

Forging relationships with innovative partner institutions to further our research is not only good for business, it’s GSL’s long-term strategy. Through our partners, we gain access to a community of researchers, some of whom lead trials that help validate results. Our partners including the following esteemed institutions:

Purposeful
& Passionate

In a dynamic and rapidly changing industry, GSL has seized on the opportunity to apply superior scientific expertise,  our unique products and patented technologies to improve the global healthcare sector by deploying an innovative genomic-based AI and quantum platform for clinical trials, point of care solutions and personalized consumer health.

DNA Technology

SUPERIOR SCIENCE, INSPIRED PRODUCTS AND EXCEPTIONAL OUTCOMES

We are a team of experienced business professionals, entrepreneurs, doctors, professors, researchers and administrators with a common goal: to improve the global healthcare sector.

" We are an innovative healthcare company with a vision to improve the global healthcare sector by deploying an innovative genomic-based AI and quantum platform for clinical trials, point of care solutions and personalized consumer health.."

We are innovators in the development of genomic-based AI and quantum platform for clinical trials.

We are thought leaders, advancing research to unlock the full potential of point of care solutions and therapies.

We provide quality and efficacy to the development of a comprehensive suite of novel, science-driven, biopharmaceuticals.

Partner Institutions

Forging relationships with innovative partner institutions to further our research is not only good for business, it’s GSL’s long-term strategy. Through our partners, we gain access to a community of researchers, some of whom lead trials that help validate results. Our partners including the following esteemed institutions:

Green Sky Labs Leadership

GREG BARON - President

BComm (Finance & Real Estate) with over 25 years of experience in commercial real estate with an extensive background in both equity and debt finance, operations and administration. Greg has negotiated and financed over $600M in real estate acquisitions.

A significant investor in Green Sky Labs with a people-focused leadership style.

REHAN HUDA (M.A.) - Executive Chairman

Having over 20 years of experience in investment banking, entrepreneurship, and corporate finance, Rehan Huda brings a brings knowledge and leadership to the company. He has helped structure and fund a number of leading edge companies in the biotechnology and information technology space.

Mr. Huda held various positions within the Canadian federal government including Senior Economist for the Department of Finance and Senior Analyst for the Natural Resources and Industry Departments. In addition, Mr. Huda was a recipient of the Canadian Government’s Public Service Award of Excellence for his financial and economic analysis related to the awarding of operating licenses to wireless telecommunication service providers.

DWAYNE DEJONG (P.ENG, MBA) – Chief Executive Officer

Dwayne brings over 25 years of experience and leadership, focused on developing and delivering technology-driven business services and solutions, providing outstanding client service, and driving profitable revenue growth in several different industries. Prior to joining Green Sky Labs in 2021, Dwayne held several leadership positions in Sales, Operations, Engineering and Finance at IBM, Bell Canada, Celestica and Lucent Technologies and has been an early investor and advisor for several Biotech/Innovation Companies.

Dwayne holds a Bachelor of Engineering and Master of Business Administration degrees from McMaster University.

SHAMSHAD HUSAIN (CPA -US) - Chief Financial Officer

Shamshad is a finance professional with extensive accounting, financial and regulatory reporting expertise. He has over 30 years of experience working mainly at professional accounting firms PWC and Deloitte, and banks such as CIBC, TD and Scotiabank. His work experience includes mainly financial reporting, controllership functions, capital management, internal controls and project management.

Shamshad is a CA (Pakistan) and a CPA from the US

My Next Health Leadership

Dr. Richard Heinzl - Chief Executive Officer

Richard Heinzl is a physician, humanitarian, entrepreneur and author whose current focus is genomics, artificial intelligence and healthcare worldwide. Based in New York and Toronto, he is currently CEO of My Next Health Inc., a next generation functional genomics company. Earlier in his career Heinzl was the founder of the Canadian chapter of Médecins Sans Frontières/Doctors Without Borders (MSF Canada), which won the Nobel Peace Prize in 1999. Recently, he was Global Medical Director for WorldCare Inc., a Boston-based, Harvard-affiliated virtual medicine company. He is a graduate of McMaster University’s Michael G. DeGroote School of Medicine and completed postgraduate degrees related to global health at Harvard University and the University of Oxford. He is an Emeritus Fellow of the American College of Preventive Medicine. His work and travels have taken him to over 80 countries and he speaks widely in North America and abroad. In 2000 he received an Honorary Doctorate (LLD) from his alma mater McMaster University was named one of the “Hundred People Who Make a Difference” in Canada by Penguin Books. In September 2016 he received the Harvard T.H. Chan School of Public Health Alumni Award of Merit, the School’s highest award.

Asif Mustafa - Chief Financial Officer

Experienced risk management, governance, audit and compliance professional.
Big Pharma International Finance and Operational Experience.
Deep Wall street exposure and currently consulting for large global banks and asset managers.
Technology product management, pre-sales and partnership alliances for major software platform.
Past experience spans senior roles in corporate development, M&A, FP&A and controllership.

DR. DAVID LIEPERT (MD) - Chief Medical Officer

Stanford trained expert in critical care medicine with over 30 years of experience as a board-certified specialist in anesthesiology. Part of the Calgary Quality Council and is an advisor with regards to surgical quality throughout the Province of Alberta. Director of Quality Assurance and Quality Improvement for the Cumming School of Medicine Department of Anesthesia, Pain and Peri- Operative Medicine as well as AHS Calgary Zone Safety. Quality Lead and National Surgical Quality Improvement Program Champion and a member of the Alberta Pain Network.

Agentix Biosciences Leadership

SALMAN HODA (MBA) - Chief Executive Officer

Over 15 years of pharmaceutical industry experience spanning operations, marketing and business development. Prior responsibilities involved identifying and evaluating assets for investment, building relationships and negotiating agreements. Lead teams of scientific, medical, legal, technical and commercial professionals to comprehensively evaluate product portfolios.

MARTIN SCHROEDER – Chief Scientific Officer

Martin brings over 25 years of success in general management, technical R&D management, marketing, corporate finance and business development. He has founded of numerous highly valued companies and startups.

Mr. Patrick McBride - Board Member

Patrick McBride brings more than 15 years of experience in the financial industry and has held several senior roles at investment banks including Genuity, Canaccord Genuity and Dundee Capital and Eight Capital. He has raised in excess of CAD $10 billion of growth capital for companies across relevant sectors including biotech, technology and commodities. In addition, Mr. McBride has an extensive M&A track record totalling over CAD $3 billion. Mr. McBride is also a CFA Charterholder.

Mr. Thomas English - Board Member

Mr. English has over 20 years of experience in the financial industry and has held numerous senior roles at investment banks including CIBC and Salman Partners.

Mr. English has provided financial solutions for both small and large cap companies across all business sectors. During his career he has been involved in transactions across the entire capital structure, including financings (debt, equity, IPO) and mergers and acquisition advisory assignments in Canada, South America and the United States.

Rehan Huda - Board Member

Having over 20 years of experience in investment banking, entrepreneurship, and corporate finance, Rehan Huda brings a brings knowledge and leadership to the company. He has helped structure and fund a number of leading edge companies in the biotechnology and information technology space.

Mr. Huda held various positions within the Canadian federal government including Senior Economist for the Department of Finance and Senior Analyst for the Natural Resources and Industry Departments. In addition, Mr. Huda was a recipient of the Canadian Government’s Public Service Award of Excellence for his financial and economic analysis related to the awarding of operating licenses to wireless telecommunication service providers.

DR. Tony Durst (Ph.D.) - Scientific Advisor

Professor Emeritus at the University of Ottawa Dr. Durst is a co-inventor on 14 patents and has received several awards including the Queen Elizabeth 60th Silver Jubilee medal in 2013. Dr. Durst was chair of three NSERC grants committees; he also served as member of US National Institute of Cancer major research program committees. During the past twenty years his research has focused on the isolation, evaluation and modification of natural products with potential medical application obtained from plants.

Kalmex Leadership

STAMOS KATOTAKIS (M. Eng., MBA) - President & CEO, Director

Mr. Katotakis is a chemical engineer with an exceptional record in the technology space. As the founder and CEO of Financial Models Company (“FMC”), he guided the company from its infancy to the status of a public company with over 500 employees and one of the pre-eminent world-wide suppliers of investment management software.

SHARIEF ZAMAN (B.Sc.) - Chief Operating Officer

Mr. Zaman is the former Managing Director, Southeast Asia and Middle East Region at Orbixa Capital International and Vice President of Orbixa Management Services, Inc. He has led operations across many countries with Orbixa’s advanced transaction technologies for traders in the financial services sector.

FAKHIR BAIG (Ph.D.) - Director

Mr. Baig is the CEO of Petro Sep, an industry leader in applying membrane technology to a wide variety of separation projects. Petro Sep has built over 100 large scale plants in many parts of the world, ranging from extraction to petroleum and water purification.

Green Sky Labs Board of Directors

REHAN HUDA- Executive Chairman and Board Member

M.A. (Economics), with over 20 years of experience in investment banking, entrepreneurship and corporate finance.
Structured and funded a number of leading-edge companies in the bio-tech and IT industries.
Guest speaker on finance at a variety of conferences and universities across Canada and internationally.

GREG BARON- President and Board Member

BComm (Finance & Real Estate) with over 25 years of experience as an entrepreneur in commercial real estate and an extensive background in both equity and debt finance, operations and administration.
Negotiated and financed over $600M in real estate acquisitions.
A significant investor in GSL with a people-focused leadership style.

JOHN AYANOGLOU - Board Member

John has served as Chief Financial Officer (CFO) of four financial services firms, three of which were publicly-listed companies, including Equitable Group (and its wholly-owned OSFI registered financial institution, currently Canada’s 9th largest schedule I bank). He has built and inspired successful teams and worked with Boards, investment bankers and others to cumulatively raise over $1 billion in common, preferred, debenture and other financing. Prior to this, John practiced with PricewaterhouseCoopers LLP (PwC), in Toronto and Boston. John holds directorships with DX Financial Mortgage Investment Corporation and Omega WealthGuard, which is a private company. He holds a double specialist degree in Commerce and Economics from the University of Toronto, and is a chartered accountant and a member of CPA Canada (CA/CPA). John has also received his ICD.D designation from the Institute of Corporate Directors at the Rotman School of Business.

ROBERT GUO- Board Member

Mr. Robert Guo is currently the President Sixty Degree Capital, a venture capital and private equity firm, Mr. Guo is a seasoned and insightful venture capital and private equity investor with years of experience investing in international markets, Prior to this, Mr. Guo was the President of an investment firm and formerly sat as a member of the Board of Directors of various public and private companies.